logo
  • Home
  • Applications
    • Indications
  • Business
  • EpiSwitch™
  • Products
    • EpiSwitch™ Service
  • Investors
    • Investors Overview
    • Results and Presentations
    • Share Price Information
    • Regulatory News
    • Board & Governance
    • Key Corporate Documents
    • AIM Rule 26
    • Email Alerts
    • Investor Contacts
  • News
  • About Us
    • History
    • Board of Directors
    • Management Team
    • Scientific Advisory Panel
    • Values
    • Careers

oxfordbiodynamics

Oxford BioDynamics to expand strategic focus

Press Release


by oxfordbiodynamics

Appointment of Chairman for Oxford Biodynamics Plc

Press Release


by oxfordbiodynamics

Strategic partnership with Boca Biolistics

Press Release


by oxfordbiodynamics

Disease severity program for COVID-19 advances

Press Release


by oxfordbiodynamics

Interim results for six months ended 31 March 2020

PDF


Press Release


by oxfordbiodynamics

Industry expert Dr Peter Pack, appointed as Non-Executive Chairman, succeeding Stephen Diggle

Press Release


by oxfordbiodynamics

Oxford BioDynamics biomarker platform is selected to help identify COVID-19 patients at risk of severe disease and profile patients who will benefit from therapeutic treatment

Press Release


by oxfordbiodynamics

Board restructure to support future growth

Press Release


by oxfordbiodynamics

Oxford BioDynamics to present at BioTech Pharma Summit: Liquid Biopsy 2020 in Lisbon, Portugal

Press Release


by oxfordbiodynamics

Oxford Biodynamics Plc enters into master service agreement with world leading US pharmaceutical company to evaluate EpiSwitch™ biomarkers

Press Release


by oxfordbiodynamics

  • 1
  • 2
  • 3
  • …
  • 9

Terms of Use / Site Map / Privacy Policy / Cookies Policy

Regulated and Licensed by Human Tissue Authority
License No. 12571
© 2002-2020 Oxford Biodynamics Plc

Privacy Preference Center

Privacy Preferences

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with this.OkRead more